RE:RE:RE:RE:RE:RE:RE:Happy new year, surprise is unfolding…I started writing something negative about ONC and refrain. Instead I'll babble.
Downsizing is positive for the current business model. I assume he left. It would be extremely difficult/frustrating to work there with such slow progress.
Silence on breast cancer trial is awesome. It means those nasty patients are surviving. The primary investigator will book a presentation at a conference the moment progress stops.
My take on breast cancer therapeutic competition, the ADCs, is there are significant problems. Please remark here. As I'm a bit clued out.
I think the stock will bottom in next couple of months, firm and then rise in anticipation of where we hoped we would be last year. We may not get an update on the breast cancer. But ADLs will be publishing at San Antonio's AACR. ONC will use that info to define and launch Phase 3. What is our target market?
I still believe Paleo is a game changer. And we will see and participate in this as the phase 3 trial progresses. Assuming this time they write in protocols to manage people with flu like symptoms correctly.
Share value should strengthen into May and grow there forward. These are my guesses.